{"id":"https://openalex.org/W2617438993","doi":"https://doi.org/10.1093/ndt/gfx134.to042","title":"TO042ANTIPROTEINURIC EFFECT OF SPARSENTAN, A DUAL ANGIOTENSIN II AND ENDOTHELIN TYPE A RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A SUBGROUP ANALYSIS OF THE DUET TRIAL","display_name":"TO042ANTIPROTEINURIC EFFECT OF SPARSENTAN, A DUAL ANGIOTENSIN II AND ENDOTHELIN TYPE A RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A SUBGROUP ANALYSIS OF THE DUET TRIAL","publication_year":2017,"publication_date":"2017-05-01","ids":{"openalex":"https://openalex.org/W2617438993","doi":"https://doi.org/10.1093/ndt/gfx134.to042","mag":"2617438993"},"language":"en","primary_location":{"id":"doi:10.1093/ndt/gfx134.to042","doi":"https://doi.org/10.1093/ndt/gfx134.to042","is_oa":false,"landing_page_url":"https://doi.org/10.1093/ndt/gfx134.to042","pdf_url":null,"source":{"id":"https://openalex.org/S186113128","display_name":"Nephrology Dialysis Transplantation","issn_l":"0931-0509","issn":["0931-0509","1460-2385"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nephrology Dialysis Transplantation","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001391327","display_name":"Loreto Gesualdo","orcid":"https://orcid.org/0000-0002-4861-0911","observed_orcids":["https://orcid.org/0000-0002-4861-0911"]},"institutions":[{"id":"https://openalex.org/I4210095088","display_name":"Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari","ror":"https://ror.org/00pap0267","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210095088","https://openalex.org/I4210099368","https://openalex.org/I4210117053"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Loreto Gesualdo","raw_affiliation_strings":["Nephrology, Dialysis and Transplantation Unit Azienda Ospedaliero-Universitaria Consorziale Bari Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nephrology, Dialysis and Transplantation Unit Azienda Ospedaliero-Universitaria Consorziale Bari Italy","institution_ids":["https://openalex.org/I4210095088"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073232899","display_name":"Kenneth V. Lieberman","orcid":"https://orcid.org/0000-0002-5772-7708","observed_orcids":["https://orcid.org/0000-0002-5772-7708"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Lieberman","raw_affiliation_strings":["Nephrology Hackensack University Medical Center Hackensack NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nephrology Hackensack University Medical Center Hackensack NJ United States","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081888215","display_name":"Vladim\u0131\u0301r Tesa\u0159","orcid":"https://orcid.org/0000-0001-6982-0689","observed_orcids":["https://orcid.org/0000-0001-6982-0689"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Vladimir Tesar","raw_affiliation_strings":["Nephrology Charles University Prague Prague Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nephrology Charles University Prague Prague Czech Republic","institution_ids":["https://openalex.org/I21250087"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069748177","display_name":"Tarak Srivastava","orcid":"https://orcid.org/0000-0002-8654-0627","observed_orcids":["https://orcid.org/0000-0002-8654-0627"]},"institutions":[{"id":"https://openalex.org/I1328594524","display_name":"Children's Mercy Hospital","ror":"https://ror.org/04zfmcq84","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1328594524"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tarak Srivastava","raw_affiliation_strings":["Nephrology Children's Mercy Hospitals Kansas City MO United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nephrology Children's Mercy Hospitals Kansas City MO United States","institution_ids":["https://openalex.org/I1328594524"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071680096","display_name":"Radko Komers","orcid":"https://orcid.org/0009-0006-7814-5324","observed_orcids":["https://orcid.org/0009-0006-7814-5324"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Radko Komers","raw_affiliation_strings":["Clinical Retrophin Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Retrophin Cambridge MA United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3474,"currency":"EUR","value_usd":3926},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"suppl_3","first_page":"iii97","last_page":"iii97"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sparsentan","display_name":"sparsentan","score":0.9940000176429749},{"id":"https://openalex.org/keywords/primary-focal-segmental-glomerulosclerosis","display_name":"primary focal segmental glomerulosclerosis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/proteinuria","display_name":"proteinuria","score":0.8610000014305115},{"id":"https://openalex.org/keywords/irbesartan","display_name":"irbesartan","score":0.7649999856948853},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9089999794960022},{"id":"https://openalex.org/keywords/urine-protein-creatinine-ratio","display_name":"urine protein-to-creatinine ratio","score":0.8140000104904175},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.8930000066757202},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9169999957084656},{"id":"https://openalex.org/keywords/ckd-stage","display_name":"CKD stage","score":0.5440000295639038},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.5460000038146973},{"id":"https://openalex.org/keywords/mutation","display_name":"genetic mutations","score":0.3409999907016754},{"id":"https://openalex.org/keywords/nephrotic-syndrome","display_name":"nephrotic syndrome","score":0.6060000061988831},{"id":"https://openalex.org/keywords/antiproteinuric-effect","display_name":"antiproteinuric effect","score":0.7020000219345093}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9326099157333374},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.522280216217041},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.5164675712585449},{"id":"https://openalex.org/C2778415529","wikidata":"https://www.wikidata.org/wiki/Q1435223","display_name":"Focal segmental glomerulosclerosis","level":4,"score":0.5111721158027649},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.49994635581970215},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4950219988822937},{"id":"https://openalex.org/C104849204","wikidata":"https://www.wikidata.org/wiki/Q24778533","display_name":"Angiotensin receptor","level":4,"score":0.4255464971065521},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.41513872146606445},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.37917813658714294},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3269262909889221},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32520991563796997},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2812158763408661},{"id":"https://openalex.org/C2780368995","wikidata":"https://www.wikidata.org/wiki/Q605006","display_name":"Glomerulonephritis","level":3,"score":0.13056090474128723},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.11417633295059204},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/ndt/gfx134.to042","doi":"https://doi.org/10.1093/ndt/gfx134.to042","is_oa":false,"landing_page_url":"https://doi.org/10.1093/ndt/gfx134.to042","pdf_url":null,"source":{"id":"https://openalex.org/S186113128","display_name":"Nephrology Dialysis Transplantation","issn_l":"0931-0509","issn":["0931-0509","1460-2385"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nephrology Dialysis Transplantation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2898491544","https://openalex.org/W2594073619","https://openalex.org/W4388302906","https://openalex.org/W4395672610","https://openalex.org/W4229027438","https://openalex.org/W2955153223","https://openalex.org/W2999129752","https://openalex.org/W2803849858","https://openalex.org/W4397025093","https://openalex.org/W7125426772"],"abstract_inverted_index":{"INTRODUCTION":[0],"AND":[1],"AIMS:":[2],"DUET,":[3],"an":[4,13],"8-week,":[5],"phase":[6],"2,":[7],"double-blind,":[8],"active-controlled":[9],"study":[10,298],"(NCT01613118)":[11],"with":[12,34,55,96,141,269,326],"open-label":[14],"extension,":[15],"evaluated":[16],"the":[17,49,56,222,293,297],"efficacy":[18,224],"and":[19,77,90,115,154,185,200,214,277,310],"safety":[20],"of":[21,67,100,105,113,120,159,212,292,305],"sparsentan":[22,35,74,114,167,251,309,318],"as":[23],"a":[24,42,97,156,322],"treatment":[25,68,230],"for":[26,161,192,262,302],"primary":[27],"focal":[28],"segmental":[29],"glomerulosclerosis":[30],"(FSGS).":[31],"Patients":[32,128],"treated":[33,268],"200,":[36],"400":[37],"or":[38,135,144,168],"800":[39],"mg/day":[40,63],"showed":[41],"greater":[43,323],"reduction":[44],"in":[45,117,171,183,221,244,248,254,275,286,312],"proteinuria":[46],"assessed":[47],"from":[48,173,246,288],"urine":[50],"protein/creatinine":[51],"ratio":[52],"(UPC)":[53],"compared":[54,325],"angiotensin":[57],"II":[58],"receptor":[59],"antagonist,":[60],"irbesartan":[61,116,184,311],"300":[62],"after":[64],"8":[65,130,210],"weeks":[66,211],"(-45%":[69],"vs.":[70,258],"-19%,":[71],"p=0.006).":[72],"Generally,":[73],"was":[75,108,299],"safe":[76],"well":[78],"tolerated.":[79],"The":[80,103],"most":[81,291],"common":[82],"adverse":[83],"events":[84],"noted":[85],"were":[86,164,175,232,252,273],"headache,":[87],"hypotension,":[88],"edema":[89],"gastrointestinal":[91],"symptoms.":[92],"DUET":[93],"involved":[94],"patients":[95,122,187,206,267,282],"wide":[98],"spectrum":[99],"baseline":[101,174,196,235,247,289],"characteristics.":[102],"aim":[104],"this":[106],"analysis":[107],"to":[109,131,137,166,218,250,321],"evaluate":[110],"antiproteinuric":[111,306],"effects":[112,307],"predefined":[118],"subgroups":[119,256],"FSGS":[121,143],"based":[123],"on":[124,155],"prognostic":[125,190,239],"factors.":[126,240],"METHODS:":[127],"aged":[129],"75":[132,138],"years":[133,139],"(U.S.)":[134],"18":[136],"(EU)":[140],"biopsy-proven":[142],"documented":[145],"genetic":[146],"mutation,":[147],"UPC":[148,172,245,287,320],"\u22651.0":[149],"g/g,":[150],"eGFR":[151],">30":[152],"mL/min/1.73m2,":[153],"stable":[157],"dose":[158],"immunosuppression":[160],"\u22651":[162],"month":[163],"randomized":[165],"irbesartan.":[169,327],"Changes":[170],"analyzed":[176],"by":[177,189,238],"Mixed-Effect":[178],"Model":[179],"Repeated":[180],"Measures":[181],"(MMRM)":[182],"sparsentan-treated":[186],"stratified":[188,237],"factors":[191],"age,":[193],"gender,":[194],"race,":[195],"proteinuria,":[197],"blood":[198],"pressure,":[199],"CKD":[201],"stage.":[202],"RESULTS:":[203],"Of":[204],"109":[205],"treated,":[207],"103":[208],"completed":[209],"treatment,":[213],"96":[215],"met":[216],"criteria":[217],"be":[219],"included":[220],"overall":[223],"analysis.":[225],"No":[226],"significant":[227,242,271,284],"differences":[228],"between":[229,308],"groups":[231],"observed":[233,253,274],"at":[234],"when":[236],"Statistically":[241],"changes":[243,272],"response":[249],"all":[255],"(p<0.05":[257],"baseline,":[259],"ANCOVA),":[260],"except":[261],"black/African":[263],"American":[264],"patients.":[265],"In":[266],"irbesartan,":[270],"nephrotic":[276],"CKD2":[278],"subgroups.":[279,295],"CONCLUSIONS:":[280],"Sparsentan-treated":[281],"demonstrated":[283],"decreases":[285],"across":[290],"prespecified":[294],"Although":[296],"not":[300],"powered":[301],"direct":[303],"comparisons":[304],"subgroups,":[313],"these":[314],"observations":[315],"suggest":[316],"that":[317],"reduced":[319],"degree":[324]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2017-06-05T00:00:00"}